Tags

Type your tag names separated by a space and hit enter

Metabolically healthy obesity and risk of incident CKD.

Abstract

BACKGROUND AND OBJECTIVES

Metabolically healthy obesity (MHO) is a unique obesity phenotype that apparently protects people from the metabolic complications of obesity. The association between MHO phenotype and incident CKD is unclear. Thus, this study investigated the association between MHO phenotype and incident CKD.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS

A total of 3136 Japanese participants were enrolled in an 8-year follow-up cohort study in 2001. Metabolically healthy status was assessed by common clinical markers: BP, triglycerides, HDL cholesterol, and fasting plasma glucose concentrations. Body mass index ≥25.0 kg/m(2) was defined as obesity. CKD was defined by proteinuria or eGFR of <60 ml/min per 1.73 m(2). To calculate the odds ratio for incident CKD, logistic regression analyses were performed.

RESULTS

The crude incidence proportions of CKD were 2.6% (56 of 2122 participants) in participants with the metabolically healthy nonobesity phenotype, 2.6% (8 of 302) in those with the MHO phenotype, 6.7% (30 of 445) in those with the metabolically abnormal nonobesity phenotype, and 10.9% (29 of 267) in those with the metabolically abnormal obesity phenotype. Compared with metabolically healthy nonobesity phenotype, the odds ratios for incident CKD were 0.83 (95% confidence interval [95% CI], 0.36 to 1.72; P=0.64) for MHO, 1.44 (95% CI, 0.80 to 2.57; P=0.22) for metabolically abnormal nonobesity, and 2.80 (95% CI, 1.45 to 5.35; P=0.02) for metabolically abnormal obesity phenotype after adjustment for confounders, including age, sex, smoking statues, alcohol use, creatinine, uric acid, systolic BP, HDL cholesterol, and impaired fasting glucose or diabetes.

CONCLUSION

MHO phenotype was not associated with higher risk of incident CKD.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Division of Metabolism, Nephrology and Rheumatology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan; and.

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    ,

    Division of Metabolism, Nephrology and Rheumatology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan; and.

    ,

    Department of Internal Medicine, Oike Clinic, Kyoto, Japan.

    ,

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan;

    Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; sayarinapm@hotmail.com.

    Source

    MeSH

    Adult
    Biomarkers
    Blood Glucose
    Body Mass Index
    Chi-Square Distribution
    Female
    Glomerular Filtration Rate
    Humans
    Incidence
    Japan
    Kidney
    Lipids
    Logistic Models
    Male
    Middle Aged
    Multivariate Analysis
    Obesity, Metabolically Benign
    Odds Ratio
    Phenotype
    Protective Factors
    Proteinuria
    Renal Insufficiency, Chronic
    Retrospective Studies
    Risk Assessment
    Risk Factors
    Time Factors

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    25635035

    Citation

    Hashimoto, Yoshitaka, et al. "Metabolically Healthy Obesity and Risk of Incident CKD." Clinical Journal of the American Society of Nephrology : CJASN, vol. 10, no. 4, 2015, pp. 578-83.
    Hashimoto Y, Tanaka M, Okada H, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015;10(4):578-83.
    Hashimoto, Y., Tanaka, M., Okada, H., Senmaru, T., Hamaguchi, M., Asano, M., ... Fukui, M. (2015). Metabolically healthy obesity and risk of incident CKD. Clinical Journal of the American Society of Nephrology : CJASN, 10(4), pp. 578-83. doi:10.2215/CJN.08980914.
    Hashimoto Y, et al. Metabolically Healthy Obesity and Risk of Incident CKD. Clin J Am Soc Nephrol. 2015 Apr 7;10(4):578-83. PubMed PMID: 25635035.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Metabolically healthy obesity and risk of incident CKD. AU - Hashimoto,Yoshitaka, AU - Tanaka,Muhei, AU - Okada,Hiroshi, AU - Senmaru,Takafumi, AU - Hamaguchi,Masahide, AU - Asano,Mai, AU - Yamazaki,Masahiro, AU - Oda,Yohei, AU - Hasegawa,Goji, AU - Toda,Hitoshi, AU - Nakamura,Naoto, AU - Fukui,Michiaki, Y1 - 2015/01/29/ PY - 2014/09/10/received PY - 2015/01/06/accepted PY - 2015/1/31/entrez PY - 2015/1/31/pubmed PY - 2016/1/9/medline KW - body mass index KW - chronic kidney disease KW - epidemiology and outcomes KW - obesity KW - proteinuria SP - 578 EP - 83 JF - Clinical journal of the American Society of Nephrology : CJASN JO - Clin J Am Soc Nephrol VL - 10 IS - 4 N2 - BACKGROUND AND OBJECTIVES: Metabolically healthy obesity (MHO) is a unique obesity phenotype that apparently protects people from the metabolic complications of obesity. The association between MHO phenotype and incident CKD is unclear. Thus, this study investigated the association between MHO phenotype and incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 3136 Japanese participants were enrolled in an 8-year follow-up cohort study in 2001. Metabolically healthy status was assessed by common clinical markers: BP, triglycerides, HDL cholesterol, and fasting plasma glucose concentrations. Body mass index ≥25.0 kg/m(2) was defined as obesity. CKD was defined by proteinuria or eGFR of <60 ml/min per 1.73 m(2). To calculate the odds ratio for incident CKD, logistic regression analyses were performed. RESULTS: The crude incidence proportions of CKD were 2.6% (56 of 2122 participants) in participants with the metabolically healthy nonobesity phenotype, 2.6% (8 of 302) in those with the MHO phenotype, 6.7% (30 of 445) in those with the metabolically abnormal nonobesity phenotype, and 10.9% (29 of 267) in those with the metabolically abnormal obesity phenotype. Compared with metabolically healthy nonobesity phenotype, the odds ratios for incident CKD were 0.83 (95% confidence interval [95% CI], 0.36 to 1.72; P=0.64) for MHO, 1.44 (95% CI, 0.80 to 2.57; P=0.22) for metabolically abnormal nonobesity, and 2.80 (95% CI, 1.45 to 5.35; P=0.02) for metabolically abnormal obesity phenotype after adjustment for confounders, including age, sex, smoking statues, alcohol use, creatinine, uric acid, systolic BP, HDL cholesterol, and impaired fasting glucose or diabetes. CONCLUSION: MHO phenotype was not associated with higher risk of incident CKD. SN - 1555-905X UR - https://www.unboundmedicine.com/medline/citation/25635035/Metabolically_healthy_obesity_and_risk_of_incident_CKD_ L2 - http://cjasn.asnjournals.org/cgi/pmidlookup?view=long&amp;pmid=25635035 DB - PRIME DP - Unbound Medicine ER -